Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 6/20 | 0.51 |
| ▸ | WNT3A | P56704 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70680 | 0.86 | KMT2A (0.45) | SCDWNT3AHPGDSPORCN | |
| SCHEMBL71143 | 0.86 | WNT3A (0.44) | WNT3AHPGDSPORCN | |
| SCHEMBL69071 | 0.86 | EPHX2 (0.45) | WNT3APORCN | |
| SCHEMBL68846 | 0.86 | SCD (0.53) | SCD | |
| SCHEMBL69520 | 0.84 | SCD (0.47) | SCDWNT3APOLBRBP4HPGDS | |
| SCHEMBL225822 | 0.83 | SCD (0.48) | SCDWNT3ATRPV1 | |
| SCHEMBL28877654 | 0.80 | SCD (0.61) | SCDPOLBRBP4 | |
| SCHEMBL70952 | 0.78 | RBP4 (0.44) | SCDRBP4 | |
| SCHEMBL70313 | 0.75 | SCD (0.58) | SCD | |
| SCHEMBL2636808 | 0.74 | SCD (0.57) | SCDPOLBRBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | claimed |
| CN-102036558-A | Novel piperidine derivatives as stearoyl-CoA desaturase inhibitors | FOREST LAB HOLDINGS LTD | 2011-04-27 | — | — | CN | claimed |
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | claimed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | claimed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | claimed |
| US-12433880-B2 | Methods for the treatment of neurological disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-07 | — | — | US | disclosed |
| EP-3566055-B1 | SCD INHIBITOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-10 | — | — | US | disclosed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3566055-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Yumanity Therapeutics, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129403-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| CN-102036558-A | Novel piperidine derivatives as stearoyl-CoA desaturase inhibitors | FOREST LAB HOLDINGS LTD | 2011-04-27 | — | — | CN | disclosed |
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | SCD 1194/4885WNT3A 4444/4885POLB 2172/4885 |
| US-12433880-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | SCD 1194/4885WNT3A 4444/4885POLB 2172/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | SCD 1/4885WNT3A 3779/4885POLB 1727/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | SCD 1194/4885WNT3A 4444/4885POLB 2172/4885 |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | SCD 1194/4885WNT3A 4444/4885POLB 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.